Description

Natera: Is Signatera’s Momentum About to Accelerate Again as Biomarker Laws Expand State by State?

Natera, Inc. has delivered robust performance for the third quarter of 2025, reflecting significant momentum and strategic advancements across its diverse product lines. The company reported revenues of $592 million, marking a 35% increase compared to the same quarter last year. This growth was bolstered by substantial volume increases throughout its portfolio and record expansion of the Signatera line. A notable highlight is the continued adoption and expansion of Signatera, particularly in the field of oncology. The company processed 202,000 clinical MRD tests in the quarter and experienced a notable 56% year-on-year growth in clinical MRD units. Signatera’s application in clinical trials, such as the IMvigor011 in bladder cancer, is of particular interest. The trial results, published in the New England Journal of Medicine, support Signatera’s efficacy in directing post-surgical cancer treatments, suggesting a potential paradigm shift in cancer care. Natera’s gross margin reached a high of 64.